Zimbabwe has initiated distribution of Lenacapavir, a revolutionary twice-yearly injectable HIV prevention drug, in what health experts call a potential turning point for sub-Saharan Africa's HIV response. The rollout began this week in Harare's Epworth suburb, prioritizing populations with limited access to daily prevention methods.
A Shift Toward Simpler Prevention
Health workers demonstrated the injection process at a community clinic where 24-year-old Precious Chiwaya became among the first recipients. "Before this, I worried constantly about clinic stockouts," she told KhabarAsia. "Now I can focus on my tailoring business without monthly anxiety."
Progress and Persistent Challenges
While Zimbabwe maintains one of Africa's highest antiretroviral therapy coverage rates at 90%, Health Minister Dr. Douglas Mombeshora notes that 13,000 new infections in 2025—mostly among young women—demand innovative solutions. "This technology respects people's realities," he said at the launch event.
Epidemiological Impact Potential
Clinical trials show 92% effectiveness when administered biannually. Public health advocates like Imelda Mahaka of Pangea Zimbabwe AIDS Trust predict particular benefits for mobile workers and stigma-affected groups: "Six-month protection removes daily negotiation with prevention."
The program initially targets 5,000 high-risk individuals through 15 clinics, with plans for nationwide expansion by late 2026.
